Could being proactive, by treating lung cancer patients with next-generation drugs, help reduce the risk of acquired resistance? In this interesting interview, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, shares his thoughts on this matter, explaining the importance of understanding the biology of lung cancer and being able to predict how the cancer will behave in the future. Dr Camidge also discusses the use of osimertinib and what could be considered when deciding on the use of this drug. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Acquired resistance: facing the challenge of immunotherapy in patients with lung cancer
